<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system

Loading...
Thumbnail Image

School / College / Institute

Item type:Organizational Unit,
Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Azar, Lena Mahmoudi

Karaman, Elif

Eyuepoglu, Alp Ertunga

Erman, Batu

Guel, Ahmet

Uysal, Serdar

Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

BackgroundThe interleukin-1 receptor antagonist (IL-1Ra) is a crucial molecule that counteracts the effects of interleukin-1 (IL-1) by binding to its receptor. A high concentration of IL-1Ra is required for complete inhibition of IL-1 activity. However, the currently available Escherichia coli-expressed IL-1Ra (E. coli IL-1Ra, Anakinra) has a limited half-life. This study aims to produce a cost-effective, functional IL-1Ra on an industrial scale by expressing it in the pyrG auxotroph Aspergillus oryzae.ResultsWe purified A. oryzae-expressed IL-1Ra (Asp. IL-1Ra) using ion exchange and size exclusion chromatography (53 mg/L). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis revealed that Asp. IL-1Ra is N-glycosylated and approximately 17 kDa in size. We conducted a comparative study of the bioactivity, binding kinetics, and half-life between Asp. IL-1Ra and E. coli IL-1Ra. Asp. IL-1Ra showed good bioactivity even at a low concentration of 0.5 nM. The in vitro half-life of Asp. IL-1Ra was determined for different time points (0, 24, 48, 72, and 96 h) and showed higher stability than E. coli IL-1Ra, despite exhibiting a 100-fold lower binding affinity (2 nM).ConclusionThis study reports the production of a functional Asp. IL-1Ra with advantageous stability, without extensive downstream processing. To our knowledge, this is the first report of a recombinant functional and stable IL-1Ra expressed in A. oryzae. Our results suggest that Asp. IL-1Ra has potential for industrial-scale production as a cost-effective alternative to E. coli IL-1Ra.

Source

Publisher

BioMed Central

Citation

item.page.haspartof

Source

BMC Biotechnology

item.page.ispartofseries

item.page.edition

DOI

10.1186/s12896-023-00785-7

item.page.datauri

item.page.link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Item type:Goal, Access status: Open Access ,
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.
Google Scholar
Scholar'da Ara ↗
3
Görüntülenme
12
İndirme
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators